MPN News for treatment primary myelofibrosis, post-PVMF, Post ET-MF and Primary myelofibrosis

[mammared]

Hello all. It has been a while but I wanted to share this latest info.

The combination of panobinostat (Farydak) and ruxolitinib (Jakafi) demonstrated efficacy and a tolerable safety profile as a treatment for patients with primary myelofibrosis (PMF) and post-polycythemia vera–related myelofibrosis (post-PV MF), and post-essential thrombocythemia–related myelofibrosis (post-ET MF), according to results of a phase I dose-escalation study that was published in Leukemia Research.

The investigators concluded that the combination of panobinostat and ruxolitinib was feasible in the patient population. Multiple combination trials were initiated during the time period that this trial was launched, limiting patient enrollment for this trial, wrote the authors. Overall, the investigators emphasized that the combination was safe and tolerable with limited toxicity.

... to read the full story